Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, National Children's Medical Center for South Central Region, Guangzhou, China.
Molecular Diagnosis and Gene Testing Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Front Immunol. 2022 May 10;13:878457. doi: 10.3389/fimmu.2022.878457. eCollection 2022.
Infiltrating immune cells have been reported as prognostic markers in many cancer types. We aimed to evaluate the prognostic role of tumor-infiltrating lymphocytes, namely CD3+ T cells, CD8+ cytotoxic T cells and memory T cells (CD45RO+), in neuroblastoma.
Immunohistochemistry was used to determine the expression of CD3, CD8 and CD45RO in the tumor samples of 244 neuroblastoma patients. We then used digital pathology to calculate the densities of these markers and derived an immunoscore based on such densities.
Densities of CD3+ and CD8+ T cells in tumor were positively associated with the overall survival (OS) and event-free survival (EFS), whereas density of CD45RO+ T cells in tumor was negatively associated with OS but not EFS. An immunoscore with low density of CD3 and CD8 (CD3-CD8-) was indictive of a greater risk of death (hazard ratio 6.39, 95% confidence interval 3.09-13.20) and any event (i.e., relapse at any site, progressive disease, second malignancy, or death) (hazard ratio 4.65, 95% confidence interval 2.73-7.93). Multivariable analysis revealed that the CD3-CD8- immunoscore was an independent prognostic indicator for OS, even after adjusting for other known prognostic indicators.
The new immunoscore based on digital pathology evaluated densities of tumor-infiltrating CD3+ and CD8+ T cells contributes to the prediction of prognosis in neuroblastoma patients.
浸润免疫细胞已被报道为许多癌症类型的预后标志物。我们旨在评估肿瘤浸润淋巴细胞(即 CD3+T 细胞、CD8+细胞毒性 T 细胞和记忆 T 细胞(CD45RO+))在神经母细胞瘤中的预后作用。
免疫组织化学用于确定 244 名神经母细胞瘤患者肿瘤样本中 CD3、CD8 和 CD45RO 的表达。然后,我们使用数字病理学来计算这些标志物的密度,并基于这些密度得出免疫评分。
肿瘤中 CD3+和 CD8+T 细胞的密度与总生存(OS)和无事件生存(EFS)呈正相关,而肿瘤中 CD45RO+T 细胞的密度与 OS 呈负相关,但与 EFS 无关。CD3 和 CD8 低密度(CD3-CD8-)的免疫评分提示死亡风险更高(危险比 6.39,95%置信区间 3.09-13.20)和任何事件(即任何部位复发、进展性疾病、第二恶性肿瘤或死亡)(危险比 4.65,95%置信区间 2.73-7.93)。多变量分析表明,CD3-CD8-免疫评分是 OS 的独立预后指标,即使在调整了其他已知的预后指标后也是如此。
基于数字病理学评估的肿瘤浸润 CD3+和 CD8+T 细胞密度的新免疫评分有助于预测神经母细胞瘤患者的预后。